CTOs on the Move

Athira

www.athira.com

 
At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer`s, so that patients can regain their memories, lives, and family relationships. We are a motivated, impassioned team committed to making a positive impact on human health.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.athira.com
  • 18706 North Creek Parkway Suite 104
    Bothell, WA USA 98011
  • Phone: 866.725.0930

Executives

Name Title Contact Details
Rachel Lenington
 Chief Technology Officer and Head of Product Development Strategy Profile
Rachel Lenington
 Chief Operating Officer Profile

Funding

Athira raised $85M on 06/04/2020
Athira raised $90M on 01/20/2021

Similar Companies

Apotex Fermentation

Apotex Fermentation, Inc. is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

University Cancer & Blood Center

University Cancer & Blood Center’s highly skilled medical professionals, whose backgrounds include working at the nation’s leading cancer centers, provide every patient with the...

Baxter Pharmaceutical Products

Baxter Pharmaceutical Products is a New Providence, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CDx Diagnostics

The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.